Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5852W HIGH $464.00
Volume
123.92 K
Value Traded
420.48 K
Short % Float
3.95%
Days to Cover
1.0
-33.07%Week
-82%1 Month
-89.7%3 Month
-98.5%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.18 M
EPS (TTM)
-7.87
P/E Ratio
-
Ent. Value
-11.53 M
Total Shares
740.97 K
Float Shares
170.00 K
Insiders
22.69%
Institutions
25.91%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SBFM Catalyst Timeline
Dated clinical, regulatory and corporate events for Sunshine Biopharma Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sunshine Biopharma Inc.
169Total events
3Upcoming
26Tier-1 (high impact)
2010 to 2026Coverage
Upcoming catalysts 2
Event history 50
▼Reverse Stock SplitCorporate
One-for-twenty reverse stock split effective to regain Nasdaq compliance
▼Equity OfferingCorporate
Pricing of $6.0 million public offering of Common Units and Series D Warrants
▲Product LaunchOndansetronPost-Market
Launch of generic Ondansetron 4mg and 8mg tablets in Canada
nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgerysource ↗
●Development Candidate NominationPreclinical
Drug candidate nominated for advanced development (PLpro protease inhibitor)
SARS Coronavirus infectionssource ↗
▲Development Candidate NominationPreclinical
Sunshine Biopharma nominates lead Coronavirus drug candidate for advanced development
SARS Coronavirus infectionssource ↗
▲IND Enabling CompletePreclinical
Lead Coronavirus drug candidate advanced into IND-enabling studies
SARS Coronavirus infectionssource ↗
▲FDA ApprovalAtenololApprovedFDA Decision
Health Canada approves Atenolol tablets
cardiovascular conditionssource ↗
▲Patent GrantedIP / Competition
U.S. Patent 12,624,066 B2 issued covering novel coronavirus treatment technology
Coronavirus infectionsource ↗
●PublicationPresentation
Anti-Coronavirus compound results published in J. Med. Chem.
Coronavirussource ↗
▼Equity OfferingCorporate
Registered direct offering of $2.46 million priced at $2.07 per share
●Product LaunchPost-Market
Planning to expand product offering to 77 generic prescription drugs over next 18 months
▲Product LaunchNIOPEGApprovedPost-Market
NIOPEG (biosimilar of NEULASTA) scheduled to be launched in remainder of 2025
decrease incidence of infection in non-myeloid malignancies patients receiving anti-neoplastic therapysource ↗
▲Product LaunchPost-Market
Nine new generic prescription drugs launched in 2025
oncology, cardiovascular health, central nervous system disorders, antimicrobialssource ↗
▲Preclinical PoCPreclinical
PLpro inhibitor showed dose-dependent antiviral activity in SARS-CoV-2-infected mice
SARS-related coronavirus infectionssource ↗
◆Pipeline PrioritizationCorporate
Planning to expand generic product offering to 86 pharmaceuticals over next two years
●PublicationPresentation
Anti-Coronavirus compound library results published in J. Med. Chem.
Coronavirussource ↗
◆Reverse Stock SplitCorporate
180-day extension to achieve Nasdaq minimum bid compliance, with potential reverse stock split if needed
▲Product LaunchNIOPEGApprovedPost-Market
NIOPEG (biosimilar of NEULASTA) scheduled to launch in 2024
decrease incidence of infection in non-myeloid malignancies patients receiving anti-neoplastic therapysource ↗
▲Product LaunchPost-Market
32 additional generic drugs scheduled to launch in remainder of 2024 and 2025
▲FDA ApprovalNIOPEGApprovedFDA Decision
Received Health Canada approval for NIOPEG (biosimilar of NEULASTA)
non-myeloid malignancies receiving anti-neoplastic therapysource ↗
▲PublicationPresentation
Published research on PLpro inhibitor with sub-micromolar potency and in vivo efficacy in mouse model
SARS-CoV-2 infectionsource ↗
▲Preclinical PoCPreclinical
Completed mouse model studies providing proof-of-concept for K1.1 mRNA Lipid Nanoparticle in hepatocellular carcinoma
human hepatocellular carcinomasource ↗
●Trial InitiationAdva-27aTrial
Phase I Clinical Trials for Adva-27a (Pancreatic Cancer, Jewish General Hospital)
Pancreatic Cancersource ↗
●Trial InitiationSBFM-PL4Trial
Phase I Clinical Trials for SBFM-PL4 (University of Georgia Affiliate Hospital)
COVID-19source ↗
▲Quarterly UpdateCorporate
Reported Q1 2023 financial results with gross revenues of $4,894,053
◆Preclinical PoCK1.1Preclinical
In vivo studies on xenograft mice using K1.1-LNP formulations expected to begin
cancersource ↗
▲Partnership / LicenseCorporate
Entered into exclusive worldwide License Agreement with University of Arizona for PLpro protease inhibitors of SARS-CoV-2
COVID-19source ↗
▲Partnership / LicenseAdva-27aCorporate
Entered into research agreement with Jewish General Hospital for IND-enabling studies of Adva-27a
cancersource ↗
●IND Enabling CompleteAdva-27aPreclinical
Research agreement signed for IND-enabling studies of Adva-27a
multidrug resistant cancersource ↗
●ATM ProgramCorporate
Announced stock repurchase program of up to $2 million under SEC Rule 10B-18
Past FDA Catalysts and PDUFA Decisions
How SBFM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
20
Drugs Scored
rNPV / MCap
Top Drug
Top 5%
Micro Cap(rank 34 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HEC-921 Small moleculeNCT07824934 | Advanced Malignant Solid Tumors | Phase 1 | RECRUITING | 110 | Jan 1, 2029 | ||||||
| HEC53856 Small moleculeNCT07891377 | Chemotherapy-induced Anemia | Phase 2 | NOT YET_RECRUITING | 160 | May 1, 2029 | ||||||
| 608 Q2W Small moleculeCompletedNCT05536726 | Psoriasis | Phase 3 | COMPLETED | 458 | Jun 4, 2024 | ||||||
| Yimitasvir Small moleculeCompletedNCT04552808 | Hepatic Impairment | Phase 1 | COMPLETED | 16 | Jun 9, 2022 | ||||||
| Yimitasvir Small moleculeCompletedNCT04565171 | Renal Impairment | Phase 1 | COMPLETED | 16 | May 7, 2022 | ||||||
| 611 Q2W Small moleculeCompletedNCT06099652 | Pulmonary Disease, Chronic Obstructive | Phase 2 | COMPLETED | 142 | Jun 18, 2025 | ||||||
| 611 Q2W Small moleculeCompletedNCT05544591 | Dermatitis, Atopic | Phase 2 | COMPLETED | 93 | Sep 20, 2023 | ||||||
| Rongliflozin Small moleculeCompletedNCT05497674 | Type 2 Diabetes Mellitus | Phase 1 | COMPLETED | 28 | Feb 24, 2023 | ||||||
| pyroglutamate rongliflozin Small moleculeCompletedNCT05374343 | Type 2 Diabetes | Phase 1 | COMPLETED | 32 | Aug 24, 2023 | ||||||
| pyroglutamate rongliflozin Small moleculeCompletedNCT05427682 | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 32 | Nov 10, 2023 | ||||||
| HEC96719 Small moleculeCompletedNCT05397379 | Non-Alcoholic Steatohepatitis | Phase 2 | COMPLETED | 68 | Sep 5, 2023 | ||||||
| 14028 Monoclonal antibodyCompletedNCT05459285 | Type 2 Diabetes | Phase 1 | COMPLETED | 68 | Jul 8, 2022 | ||||||
| HEC53856 Small moleculeCompletedNCT04925661 | Chronic Kidney Diseases | Phase 1 | COMPLETED | 40 | Aug 29, 2023 | ||||||
| HEC53856 Small moleculeCompletedNCT04925674 | Hemodialysis | Phase 1 | COMPLETED | 60 | Oct 19, 2022 | ||||||
| Z650 Small moleculeCompletedNCT03888092 | Esophageal Squamous Cell Carcinoma | Phase 1 | COMPLETED | 81 | Dec 13, 2022 | ||||||
| GLS4 Small moleculeCompletedNCT04147208 | Chronic HBV Infection | Phase 2 | COMPLETED | 250 | Sep 14, 2023 | ||||||
| HEC74647PA Small moleculeCompletedNCT05395416 | Chronic HCV Infection | Phase 2 | COMPLETED | 514 | Apr 11, 2023 | ||||||
| HEC122505MsOH Small moleculeCompletedNCT04625361 | Parkinson Disease | Phase 1 | COMPLETED | 106 | Jan 6, 2022 | ||||||
| 601 Small moleculeCompletedNCT04667897 | Branch Retinal Vein Occlusion | Phase 3 | COMPLETED | 411 | Jul 13, 2022 | ||||||
| 601 Small moleculeCompletedNCT04667910 | Central Retinal Vein Occlusion | Phase 2 | COMPLETED | 60 | Nov 16, 2022 | ||||||
| Clifutinib with Small moleculeCompletedNCT05454098 | Acute Myeloid Leukemia in Children | Phase 1 | COMPLETED | 40 | Dec 8, 2022 | ||||||
| HEC73077 Small moleculeCompletedNCT05492630 | Diabetic Nephropathy | Phase 1 | COMPLETED | 138 | Jan 4, 2023 | ||||||
| Antaitavir Hasophate Small moleculeCompletedNCT05446233 | Undisclosed | Phase 1 | COMPLETED | 6 | Jan 2, 2023 | ||||||
| Yiqibuvir Small moleculeCompletedNCT05998304 | Undisclosed | Phase 1 | COMPLETED | 8 | Sep 12, 2023 | ||||||
| HEC116094 Small moleculeCompletedNCT04982913 | Influenza | Phase 1 | COMPLETED | 118 | Oct 2, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every SBFM program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| NATAN DAVIDDirector | Grant/Award | 100,000 100,000 held | $0.00 | 04/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SBFM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SBFM for Q2 2026. | ||||
SBFM Institutional Ownership Trends
SBFM Short Interest
Shares sold short, counted twice a month.
3.95%
Short % of Float
of tradable shares sold short
840.9K
Shares Sold Short
+539.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
28.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SBFM ranks across every disease it competes in
Competitive Position is a premium feature
See how SBFM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSBFM News
SBFM▼ -22.5%on this news
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
Sunshine Biopharma announced a one for twenty reverse stock split, effective October 26, 2026, to comply with NASDAQ's minimum bid price requirement. This action will reduce the company's outstanding shares from 15,219,383 to approximately 760,969. The company has 60 generic drugs available and plans to launch 12 more by year-end.
Read more →SBFM▼ -21.4%on this news· ran to -43% by day 3
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
Sunshine Biopharma Inc. has successfully closed a public offering, raising approximately $6.0 million. The offering included Common Units and Series D Warrants, with potential additional proceeds of $14.4 million if warrants are exercised. The funds will be utilized for general corporate purposes and working capital. The company also continues to expand its generic drug offerings.
Read more →SBFM▼ -38.6%on this news· ran to -66% by day 3shared move
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
Sunshine Biopharma Inc. has announced the pricing of a public offering expected to raise approximately $6 million. The offering includes Common Units and Pre-Funded Units, with immediate exercisability for certain warrants. The proceeds are intended for general corporate purposes and working capital. The transaction is anticipated to close on October 9, 2026, pending customary conditions.
Read more →SBFM▼ -8.6%on this news
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
Sunshine Biopharma has launched generic Ondansetron tablets in Canada, enhancing its oncology supportive care portfolio. The product, available in 4mg and 8mg doses, aims to address nausea and vomiting associated with cancer treatments. This launch reflects the company's strategic expansion into a growing market, supported by a strong distribution network through its subsidiary, Nora Pharma Inc.
Read more →SBFMSunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Sunshine Biopharma has advanced its lead Coronavirus drug candidate into IND-enabling studies, showcasing promising laboratory results. The candidate exhibits potent inhibition against SARS-CoV-2 variants and favorable pharmacokinetic properties. CEO Dr. Steve Slilaty emphasized the strategic importance of this development, highlighting its potential to influence future coronavirus therapeutics. The company is also expanding its drug portfolio with additional launches planned for 2026.
Read more →SBFMHealth Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
Sunshine Biopharma has received approval from Health Canada for its Atenolol tablets, available in 25mg, 50mg, and 100mg dosages. Atenolol, a beta-blocker, is used to manage hypertension, angina pectoris, and improve survival rates post-heart attack. The company anticipates shipping the drug to pharmacies by the end of 2026, marking a strategic expansion in cardiovascular treatments.
Read more →SBFM▼ -19.8%on this news
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
Sunshine Biopharma has announced the issuance of U.S. Patent No. 12,624,066 B2, which covers its innovative compounds aimed at treating coronavirus infections. The patent protects small molecule inhibitors that target a viral enzyme crucial for immune suppression. This development is seen as a significant milestone for the company, emphasizing its commitment to addressing current and future viral threats.
Read more →SBFM▼ -13.7%on this news· ran to -28% by day 1
Sunshine Biopharma Inc. Announces Pricing of
Sunshine Biopharma Inc. has announced the pricing of a $6.0 million public offering, consisting of 12,000,000 Common Units at a price of $0.50 each. The offering is expected to close on May 19, 2026, pending customary closing conditions. The company plans to use the net proceeds to support its general corporate purposes and working capital. Additionally, Sunshine Biopharma is currently working on developing life-saving medicines in various therapeutic areas, including oncology and antivirals.
Read more →SBFM▲ +11.5%on this news
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
Sunshine Biopharma (SBFM) reported a fiscal 2025 revenue of $36.3 million, marking a 4.1% increase from 2024. The company has launched nine new generic drugs and continues to advance its proprietary antiviral research. Despite an increased net loss of $5.98 million due to higher general and administrative expenses and an impairment charge, management is optimistic about future growth opportunities and profitable operations. Cost-reduction strategies are being implemented to focus on achieving profitability in the coming years.
Read more →SBFM▼ -5%on this news
Sunshine Biopharma Reports 2025 First
Sunshine Biopharma Inc. reported a significant 18% increase in revenues for the first quarter of 2025, compared to the previous year, showcasing strong financial results. CEO Dr. Steve Slilaty emphasized the company's commitment to innovation and sustainable growth as it aims to expand its product pipeline. Despite positive revenue growth, the company recorded a net loss of $1,179,771, albeit improved from the prior year's loss. Sunshine Biopharma is also gearing up to launch new medications, including NIOPEG, a biosimilar for cancer patients.
Read more →SBFM▼ -18.2%on this news· ran to -36% by day 3
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Sunshine Biopharma Inc. has announced a registered direct offering of approximately $2.46 million, selling common stock at $2.07 per share. The offering is expected to close around April 3, 2025, pending customary conditions. Proceeds will be utilized for general corporate purposes and working capital. This transaction reflects Sunshine Biopharma's ongoing efforts to strengthen its financial position as it continues developing various life-saving therapeutic products.
Read more →SBFM▲ +8.9%on this newsshared move
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
Sunshine Biopharma Inc. (SBFM) reported a significant revenue increase, reaching $34.9 million in fiscal 2024, a 45% rise compared to the previous year. The company successfully launched 13 new generic prescription drugs and received approval for the oncology drug NIOPEG. Additionally, Sunshine Biopharma published research showcasing a new Coronavirus PLpro inhibitor with strong efficacy. Despite these successes, the company faced a net loss of $5.1 million, reflecting rising administrative costs.
Read more →SBFMSUNSHINE BIOPHARMA ANNOUNCES THE APPOINTMENT OF NEW CHIEF COMMERCIAL OFFICER
Sunshine Biopharma Inc. (SBFM) has appointed Mr. Michel Roy as its new Chief Commercial Officer, effective immediately. Mr. Roy, who has over 20 years of experience in the pharmaceutical industry, will oversee the company's commercial strategy, including sales and marketing. The transition comes as Sunshine Biopharma prepares to launch additional drugs in 2025, enhancing its market presence and growth trajectory. CEO Dr. Steve Slilaty expressed confidence in Mr. Roy's ability to contribute significantly to the company's objectives.
Read more →SBFM▼ -6.3%on this news
SUNSHINE BIOPHARMA REPORTS 2024 THIRD QUARTER
Sunshine Biopharma Inc. reported significant growth in its 2024 third quarter financial results, with gross revenues reaching $8,435,178, marking a 42% increase from the previous year. Year-to-date revenues have surged by 54%, driven primarily by new product launches and enhanced marketing efforts. Despite the revenue increase, the company faced a net loss of $1,197,803 for the quarter. The management emphasizes their strategy of pursuing profitability while continuing to expand their product offerings in oncology and antivirals.
Read more →SBFM▲ +5.8%on this news
SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER
Sunshine Biopharma, Inc. has reported substantial growth in its financial performance for the second quarter of 2024, with revenues reaching $9.3 million, a 67% increase compared to the same quarter last year. Year-to-date revenues also saw a significant rise of 61%, attributed to new product launches and expanded marketing efforts. However, the company continues to face challenges, reporting a net loss despite these revenue gains. CEO Dr. Steve Slilaty expressed confidence in the company's strategies for achieving profitability and sustainable growth.
Read more →SBFM▼ -17.8%on this news
SUNSHINE BIOPHARMA REPORTS 2024 FIRST QUARTER
Sunshine Biopharma, Inc. (SBFM) announced its financial results for the first quarter of 2024, reporting a 54% increase in gross revenues, reaching $7,541,046 compared to $4,894,053 in Q1 2023. The growth is attributed to new product launches and expanded marketing efforts by its subsidiary, Nora Pharma Inc. Despite the revenue growth, the company continues to report a net loss, although it has decreased from the previous year. Sunshine Biopharma is preparing to launch additional drugs, including a biosimilar to NEULASTA, furthering its commitment to drug development in oncology and antiviral treatments.
Read more →SBFMSUNSHINE BIOPHARMA REPORTS OPERATING RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 Sales Grew at an Average Rate of 14% Per Quarter During the Year NEW YORK, NY / ACCESSWIRE /
Sunshine Biopharma Inc. reported its fiscal year 2023 operating results, highlighting a strong sales growth of 14% per quarter. Total sales reached over $24 million with a notable increase in gross profit compared to the previous year. Despite these positive trends, the company still faced a net loss, albeit significantly reduced from 2022. Looking ahead, Sunshine Biopharma aims to expand its drug offerings and continue its growth trajectory into 2024 and beyond.
Read more →SBFMSunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering NEW YORK, FEBRUARY 13, 2024 -- Sunshine Biopharma, Inc. (NASDAQ: SBFM) (the "Company"), a pharmaceutical company offering and resea
Sunshine Biopharma, Inc. has announced a $10 million underwritten public offering consisting of 71,428,571 units priced at approximately $0.14 per unit. The offering is expected to close on or about February 15, 2024, subject to customary closing conditions. The proceeds from this offering will be utilized for general corporate purposes and working capital. Aegis Capital Corp. is acting as the sole book-running manager for this offering, indicating a structured approach to capital raise. Sunshine Biopharma has a growing portfolio of prescription drugs and is actively developing proprietary treatments.
Read more →SBFMSunshine Biopharma Moves Principal Office to New York City
Sunshine Biopharma, Inc. has announced the relocation of its headquarters from Montreal to New York City, which is expected to enhance its operational capabilities and market presence. The new office is located at 1177 Avenue of the Americas, while the company will retain a satellite office in Canada. Sunshine Biopharma aims to expand its generic drug offerings and is involved in developing new therapies for liver cancer and COVID-19. The move reflects the company's strategic growth initiatives in the competitive pharmaceutical landscape.
Read more →SBFMSUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION
Sunshine Biopharma Inc. has received a 180-day extension from Nasdaq to meet the minimum $1.00 bid price requirement for its common stock, extending the deadline to March 18, 2024. This extension allows the company time to regain compliance without immediate impact on its stock listing or trading. The firm plans to address this compliance issue, potentially through a reverse stock split, while also expanding its portfolio of generic drugs and continuing its proprietary drug development across several indications.
Read more →About Sunshine Biopharma Inc.
Headquarters333 LAS OLAS WAY, FORT LAUDERDALE, FL, 33301
BIOPHARMAWATCH ELITE PLUS
Trade the next SBFM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime